Cellares and Lyell Immunopharma announced Lyell will evaluate Cellares’ automated manufacturing platform, the Cell Shuttle, through Cellares’ Technology Adoption Partnership program. As part of the collaboration, the companies have agreed on a proof-of-concept technology transfer process for the manufacture of Lyell’s LYL797 CAR T-cell therapy, using the Cell Shuttle.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on LYEL:
- Cellares and Lyell to Evaluate Automated Manufacturing of Lyell’s CAR T-Cell Therapy on Cellares’ Cell Shuttle Platform
- Lyell Immunopharma to Participate in Upcoming Investor Conferences
- Lyell Immunopharma downgraded to Neutral from Overweight at JPMorgan
- Lyell Immunopharma reports Q2 net loss $45.6M vs. Q2 net loss $10.3M last year
- Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2023
